secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127029
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates
---------------------------------------------------------------------------

- Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.
- Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) enrolling; enrollment completion targeted H1 2025.
- KSI-101 APEX study enrolling; dose selection for pivotal studies expected Q2 2025.
- Tarcocimab ocular half-life 20 days (3x faricimab, 2-3x aflibercept) presented at Sept R&D Day.
- Preclinical ABCD pipeline expanded to glaucoma and geographic atrophy programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/0000950170-24-127029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/kod-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer